REPL Stocks Surge 127% After FDA Panel Backs Melanoma Therapy RP1
Replimune Group, Inc. (REPL) announced on Thursday that an FDA advisory panel voted 10-3 in favor of its experimental melanoma therapy RP1. Shares soared 127% in after-hours trading. The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee found results from a key clinical study both
LucasBennett·07-31 00:14
